Charles Swanton

Charles Swanton has transformed understanding of how intratumoral heterogeneity drives drug resistance through the TRACERx study, demonstrating that extensive clonal diversity within individual tumors ensures that drug-resistant subclones pre-exist before therapy begins. His research showed that chromosomal instability generates the genetic diversity that fuels resistance evolution and that parallel evolution of resistance occurs across multiple tumor regions simultaneously. He established that high heterogeneity at diagnosis predicts poor response to targeted therapy and immunotherapy. His evolutionary framework for understanding cancer drug resistance has informed strategies to target truncal (clonal) rather than branched (subclonal) alterations.